A detailed publication in The Lancet Neurology revealed the four patients who died after treatment—three in 2020 and one in 2021—all had evidence of cholestasis prior to treatment, likely caused by their disease but exacerbated by Astellas’ gene therapy. The pre-existing liver disease in children with X-linked myotubular myopathy (XLMTM) was “largely unrecognized” when the study started, according to the journal publication. Their deaths prompted the re-examination.
The first three patients had received a higher dose. An FDA clinical hold was placed in June 2020 then lifted in December 2020 as the dosing was cut in half. The trial was again placed on hold following the fourth death and remains in place.
“Important issues related to liver health in participants with XLMTM receiving gene therapy have been identified and will continue to require careful evaluation,” Perry Shieh, the principal investigator for the ASPIRO trial, said in a statement.
Caused by variations in the MTM1 gene, XLMTM is a rare genetic disease present from birth that causes extreme muscle weakness. Due to the severe breathing problems that develop, patients with XLMTM usually survive only into early childhood. Regular motor milestones are delayed or never achieved and supportive care are the only options, including ventilators and feeding tubes.
Astellas’ AT132 is an adeno-associated viral vector gene therapy designed to replace the mutated MTM1 gene to treat the devastating disease.
In the Astellas trial, 24 boys were dosed with AT132. All were ventilator-dependent and only three were able to sit independently for 30 seconds with no additional milestones achieved. By the data cutoff date, 16 participants—10 at the higher dose and 6 at the lower dose—had achieved ventilator independence and eight were able to walk independently. Several other motor milestones were also achieved. None of the 14 patients in the non-treated cohort were able to achieve ventilator independence.
With these results, Astellas contends AT132 could still be a viable treatment for the fatal disease.
“While we continue our efforts to address the ongoing clinical hold for ASPIRO, this publication serves to provide information that may guide efforts aimed at advancing promising therapies for XLMTM,” Richard Wilson, senior vice president of genetic regulation at Astellas, said in a statement.
In June 2023, Astellas announced an exclusive licensing deal with Kate Therapeutics for KT430, a next-gen gene therapy for XLMTM that utilizes a new MyoAAV capsid. The capsids are engineered to deliver therapeutic genes more effectively to muscles, at much lower doses of up to 250 times lower than what is needed with traditional AAVs like AT132. Animal studies showed MyoAAVs largely avoid the liver, potentially avoiding the serious adverse effects seen in the AT132 trial. The asset is currently in IND-enabling studies.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services